

Does nicorandil instead of supranormal potassium safely provide cardioplegia?

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
25/01/2006	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
25/09/2006	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
07/01/2021	Circulatory System	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Dag Sorlie

Contact details

Breivika
Tromsoe
Norway
9038
+47 7762 6000
dag.sorlie@unn.no

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Does nicorandil instead of supranormal potassium safely provide cardioplegia?

Study objectives

Nicorandil instead of supranormal potassium in cardioplegia is feasible, providing cardiac arrest and protection.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Helse Nord research fund.

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Angina pectoris

Interventions

Two groups of cardioplegia randomised to receive either:

1. Standard St. Thomas Hospital Solution (high [16 mM] potassium cardioplegia)
2. Nicorandil

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Nicorandil

Primary outcome(s)

1. Creatine Kinase Myocardial Band (CKMB)
2. Troponin
3. Cardiac Index (CI)
4. Saphenous Vein (SV)
5. Systemic Vascular Resistance (SVR)
6. Heart rate (HR)
7. Time to arrest

Key secondary outcome(s))

Quality of life

Completion date

26/09/2005

Eligibility

Key inclusion criteria

1. Aged 40 to 75 years
2. Elective to Coronary Artery Bypass Graft (CABG)
3. Ejection Fraction (EF) more than 40%

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

50

Key exclusion criteria

1. Concomitant procedures
2. Emergency procedures
3. Glibenclamid medication
4. Pregnancy

Date of first enrolment

24/01/2005

Date of final enrolment

26/09/2005

Locations

Countries of recruitment

Norway

Study participating centre

Breivika

Tromsoe

Norway

9038

Sponsor information

Organisation

University Hospital of North Norway (Norway)

ROR

<https://ror.org/030v5kp38>

Funder(s)

Funder type

Government

Funder Name

Local Health Authorities

Funder Name

University Hospital of North Norway

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	10/07/2006	07/01/2021	Yes	No